after joining the study you attend a baseline visit where your medical history and skin condition are recorded.

the severity of vitiligo on the face and the rest of the body is measured using the facial vitiligo area scoring index (f‑vas i) and the total vitiligo area scoring index (t‑vas i).

blood samples may be taken to check overall health.

you receive a subcutaneous injection of the study medication.

the injection contains either g ia632 or a placebo that looks the same.

the dose is described as 00 df dosage form and is given by a qualified professional.

the exact schedule for further injections is defined by the study protocol.

you return for study visits at week 12, week 24, week 36 and week 48.

at each visit the same skin scores (f‑vas i and t‑vas i) are repeated to see any changes.

your safety is checked by asking about side effects and by performing routine examinations.

additional injections may be given according to the predetermined schedule.

at week 24 the main outcome is measured: the percentage change from the baseline value of the f‑vas i score.

this assessment determines how much repigmentation has occurred on the face.

the study continues with visits at week 36 and week 48 to collect further information on efficacy and safety.

final evaluations include the achievement of predefined improvement levels (for example, 75 % improvement in f‑vas i) and the recording of any adverse events.